Exploring the Evolving Scope of Neoadjuvant Immunotherapy in NSCLC

Area of Science:

• Oncology
• Immunology

Background:

• Lung cancer is a leading cause of cancer death globally.
• Recent advances in immunotherapy, specifically immune checkpoint inhibitors, have improved survival rates for non-small cell lung cancer (NSCLC).
• Current immunotherapy benefits are mainly observed in advanced or metastatic disease.

Purpose of the Study:

• To review the efficacy and safety data of neoadjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC).
• To identify key questions for establishing the role of neoadjuvant immunotherapy in NSCLC treatment.

Main Methods:

• Comprehensive narrative review of recent early phase and ongoing phase III clinical trials.
• Evaluation of efficacy and safety data from studies assessing neoadjuvant immunotherapy in NSCLC.

Main Results:

• Immunotherapy shows promise in the neoadjuvant setting for resectable NSCLC.
• Early data suggests potential benefits, but further investigation is required.

Conclusions:

• Neoadjuvant immunotherapy may extend survival benefits to earlier stages of NSCLC.
• Further research is needed on surrogate markers, liquid biopsies, combination therapies, and adjuvant treatment strategies.